Drug application
SUMATRIPTAN AND NAPROXEN SODIUM (NAPROXEN SODIUM, SUMATRIPTAN SUCCINATE)
Drugs@FDA ANDA 207457 · AUROBINDO PHARMA LTD
Key facts
| Drug name | SUMATRIPTAN AND NAPROXEN SODIUM |
|---|---|
| Active ingredients | NAPROXEN SODIUM, SUMATRIPTAN SUCCINATE |
| Application type | ANDA |
| Application number | 207457 |
| Company | AUROBINDO PHARMA LTD |
| Dosage forms | TABLET, ORAL |
| Strength | 500MG;EQ 85MG BASE |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Feb 15, 2018 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: